Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 445Carcinoma, Non-Small-Cell Lung 224Breast Neoplasms 189Ovarian Neoplasms 167Glioblastoma 156Neoplasms 126Carcinoma, Hepatocellular 124Rectal Neoplasms 112Colonic Neoplasms 107Neoplasm Metastasis 104Brain Neoplasms 96Lung Neoplasms 91Fallopian Tube Neoplasms 85Carcinoma, Renal Cell 71Glioma 69Pancreatic Neoplasms 54Gliosarcoma 43Melanoma 42Liver Neoplasms 42Uterine Cervical Neoplasms 40Stomach Neoplasms 37Adenocarcinoma of Lung 36Recurrence 33Astrocytoma 30Endometrial Neoplasms 27Carcinoma, Ovarian Epithelial 27Triple Negative Breast Neoplasms 26Prostatic Neoplasms 22Kidney Neoplasms 22Esophageal Neoplasms 21

Interventions

atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1GSK 1363089 1Erlotinib Hydrochloride 1Disulfides 1Contrast Media 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Papillary renal cell carcinoma, sporadic × Bevacizumab × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡